DZ3209A1 - Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine. - Google Patents

Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.

Info

Publication number
DZ3209A1
DZ3209A1 DZ003209A DZ003209A DZ3209A1 DZ 3209 A1 DZ3209 A1 DZ 3209A1 DZ 003209 A DZ003209 A DZ 003209A DZ 003209 A DZ003209 A DZ 003209A DZ 3209 A1 DZ3209 A1 DZ 3209A1
Authority
DZ
Algeria
Prior art keywords
migraine
treatment
receptor antagonists
antagonists used
iglur5 receptor
Prior art date
Application number
DZ003209A
Other languages
English (en)
French (fr)
Inventor
David Bleakman
Amy Suzon Chappell
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DZ3209A1 publication Critical patent/DZ3209A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ003209A 1999-07-06 2000-06-27 Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine. DZ3209A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number Publication Date
DZ3209A1 true DZ3209A1 (fr) 2001-01-11

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003209A DZ3209A1 (fr) 1999-07-06 2000-06-27 Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.

Country Status (28)

Country Link
US (4) US6566370B1 (da)
EP (1) EP1200073B1 (da)
JP (1) JP4619595B2 (da)
KR (1) KR20020024300A (da)
CN (1) CN1230174C (da)
AR (1) AR029373A1 (da)
AU (1) AU773304B2 (da)
BR (1) BR0012175A (da)
CA (1) CA2378613C (da)
CZ (1) CZ20014488A3 (da)
DE (1) DE60032905T2 (da)
DK (1) DK1200073T3 (da)
DZ (1) DZ3209A1 (da)
EA (1) EA004290B1 (da)
ES (1) ES2278619T3 (da)
HK (1) HK1047036A1 (da)
HR (1) HRP20020013A2 (da)
HU (1) HUP0202253A3 (da)
IL (1) IL146697A0 (da)
MX (1) MXPA01012726A (da)
MY (1) MY133503A (da)
NO (1) NO20016246L (da)
NZ (1) NZ515616A (da)
PE (1) PE20010299A1 (da)
PT (1) PT1200073E (da)
SK (1) SK112002A3 (da)
TR (1) TR200200066T2 (da)
WO (1) WO2001001972A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
AU2002227020A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE397931T1 (de) * 2001-01-05 2008-07-15 Lilly Co Eli Exzitatorische aminosäure-rezeptor-antagonisten
AU2002228736A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
IL156138A0 (en) * 2001-01-05 2003-12-23 Lilly Co Eli Excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
NZ535245A (en) 2002-04-26 2007-11-30 Lilly Co Eli Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgesics
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
DK2061465T3 (da) 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
AU2007325629A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP3661500A1 (en) 2017-07-31 2020-06-10 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
AU2019232630A1 (en) 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Assays to detect neurodegeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
IL132086A0 (en) 1997-04-07 2001-03-19 Lilly Co Eli Pharmacological agents
EP1208087B1 (en) * 1999-07-06 2003-05-14 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

Also Published As

Publication number Publication date
US20050159445A1 (en) 2005-07-21
TR200200066T2 (tr) 2002-04-22
EP1200073A2 (en) 2002-05-02
AU773304B2 (en) 2004-05-20
HUP0202253A2 (hu) 2002-11-28
US6759418B2 (en) 2004-07-06
IL146697A0 (en) 2002-07-25
SK112002A3 (en) 2003-05-02
JP2003503449A (ja) 2003-01-28
EP1200073B1 (en) 2007-01-10
US20030199546A1 (en) 2003-10-23
US7157582B2 (en) 2007-01-02
WO2001001972A3 (en) 2001-12-06
CN1359289A (zh) 2002-07-17
DK1200073T3 (da) 2007-05-07
HRP20020013A2 (en) 2003-08-31
NO20016246L (no) 2002-03-04
EA200200132A1 (ru) 2002-06-27
WO2001001972A2 (en) 2001-01-11
AR029373A1 (es) 2003-06-25
EA004290B1 (ru) 2004-02-26
US6566370B1 (en) 2003-05-20
KR20020024300A (ko) 2002-03-29
HK1047036A1 (zh) 2003-02-07
PT1200073E (pt) 2007-03-30
JP4619595B2 (ja) 2011-01-26
CN1230174C (zh) 2005-12-07
MXPA01012726A (es) 2002-07-02
DE60032905T2 (de) 2007-10-18
CA2378613C (en) 2007-10-02
PE20010299A1 (es) 2001-03-07
CZ20014488A3 (cs) 2003-01-15
BR0012175A (pt) 2002-03-05
HUP0202253A3 (en) 2003-12-29
AU5873200A (en) 2001-01-22
ES2278619T3 (es) 2007-08-16
US6855823B2 (en) 2005-02-15
DE60032905D1 (de) 2007-02-22
MY133503A (en) 2007-11-30
US20040192722A1 (en) 2004-09-30
NO20016246D0 (no) 2001-12-19
CA2378613A1 (en) 2001-01-11
NZ515616A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
DZ3209A1 (fr) Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
DE60010722D1 (de) Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
MA26852A1 (fr) Agonistes selectifs du recepteur ep4 pour le traitement de l'osteoporose
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
DE60020327D1 (de) Wasserbehandlungsvorrichtung
DE60230773D1 (de) Harnstoff-derivate als vanilloid-rezeptor-antagonisten für die schmerzbehandlung
NO20011025L (no) Selektiv behandling av endoteliale somatostatinreseptorer
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
BR9809071A (pt) Agentes farmacológicos
NO20016053D0 (no) IL-8 reseptor-antagonister
NO20016052L (no) IL-8-reseptor-antagonister
MA25265A1 (fr) Antagoniste du recepteur de vitronectime.
ATE358483T1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DK1180028T3 (da) IL-8-receptorantagonister
FR2814367B1 (fr) Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
NO20020008D0 (no) Anvendelse av cortisol antagonister i behandling av hjertesvikt
DE60016769D1 (de) Antagonisten des vitronectin-receptors
NO20015774L (no) IL-8 reseptorantagonister
MXPA03000500A (es) Uso de antagonistas del receptor de isoleucina 8 en el tratamiento de infecciones por virus.
NO20022142D0 (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
ITMI20031433A1 (it) Apparecchio e metodo di trattamento dell'acqua potabile per la preparazione di acqua per uso topico a scopo detergente, cosmetico e/o terapeutico
ITBS20000024A0 (it) Dispositivo di intercettazione filtraggio e bilanciamento dell'acquaerogata in impianti idrosanitari
NO20016102D0 (no) IL-8 reseptorantagonister